Inventiva stock breaks below its €3.14 support ahead of results
The Dijon-based biotech ends the session in the red, accumulating a decline of nearly 24% over the month. The move comes as first-half 2026 results are expected on Friday.
A support breached during the session amid marked technical oversold conditions
Inventiva closes the day at €3.07, down 2.39% compared to the previous session, after breaking through its €3.14 support downward during trading without managing to reclaim it. This breach is notable: this level had served as a floor for several weeks, and the close below this threshold opens less charted territory. The decline is also evident in duration: the stock is losing nearly 10% over the week and nearly 24% over the month, in a market that is holding its ground (the SBF 120 closed with a slight gain of 0.24%). The RSI at 25 reflects outright oversold conditions, where an RSI below 30 signals potential exhaustion of sellers, but not necessarily imminent recovery.
With a ranking of 115 out of 120 values within the SBF 120, Inventiva is among the steepest declines in the index on Tuesday. The next identified resistance is placed at €4.25, approximately 39% above the current price, which gives a measure of the distance to be covered. The three moving averages are also weighing on the stock: the 20-day MA at €3.77 and the 50-day MA at €3.87 present short-term resistance, while the 200-day MA at €4.32 remains nearly 29% above the current price.
Half-year results Friday, in a context of cash position under close scrutiny
The financial results for the first half of 2026 are expected on Friday, September 25, and they will come in an already charged atmosphere. When publishing H1 2026 results on July 30, Inventiva had posted cash that rebounded to €166 million thanks to a fundraising completed in early June, but with no revenue recorded, compared to €4.5 million a year earlier. The company had then warned that its cash horizon extended only to the end of the second quarter of 2027 in the absence of additional financing.
On the pipeline front, the appointment of Chris Benecchi as Chief Operating Officer in early September had been presented as preparation for the results of the pivotal Phase 3 NATiV3 study, expected in the fourth quarter of 2026. These clinical data now hold the spotlight: they represent the main valuation driver for the company, listed on both Euronext Paris (Compartment B) and Nasdaq since July 2020. Friday's half-year results will be scrutinized primarily for an update on the cash trajectory and any clarifications on the NATiV3 timeline.
